Nifty
:
23398.10
Sensex
:
74781.76
-79.70 (-0.34%)
-120.83 (-0.16%)
Nifty
Sensex
:
:
23398.10
74781.76
-79.70 (-0.34%)
-120.83 (-0.16%)

Aurobindo Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
75/99

BSE: 524804 | NSE: AUROPHARMA

NSE BSE
1679.80
11-Sep-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1666.7
  •  1681.4
  •  1655.5
  •  1668.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  494251
  •  826711359.5
  •  1717
  •  1066.8

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 96,401.69
  • 25.97
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 94,207.60
  • 0.24%
  • 2.48

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.88%
  • 0.49%
  • 5.36%
  • FII
  • DII
  • Others
  • 16.38%
  • 21.75%
  • 4.14%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.48
  • 7.49
  • 5.08

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.10
  • 9.23
  • 3.13

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.29
  • 5.77
  • 3.37

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.96
  • 19.74
  • 22.15

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.18
  • 1.90
  • 2.22

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.66
  • 9.44
  • 10.71

Earnings Forecasts:

(Updated: 12-09-2026)
Description
2026
2027
2028
2029
Adj EPS
71
0
20.28
61.98
P/E Ratio
23.66
-
82.83
27.10
Revenue
20.12
17.41
15.95
33519.1
EBITDA
38852.1
42894.4
46232.6
6849.16
Net Income
8053.12
9044.07
9991.2
3599.77
ROA
4303.45
4981.17
4794.82
7.12
P/B Ratio
-0.42
-0.27
-0.21
2.74
ROE
2.2
1.98
1.77
10.49
FCFF
11.3
11.77
11.56
2473.7
FCFF Yield
1690.36
3401.1
4262.79
2.81
Net Debt
1.92
3.86
4.84
-1504.54
BVPS
-4019.15
-6185.03
-7844.2
612.86

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
9,150.35
7,868.14
16.30%
8,853.34
8,382.12
5.62%
8,645.90
7,978.52
8.36%
8,285.70
7,796.07
6.28%
Expenses
7,269.29
6,265.11
16.03%
7,100.56
6,590.20
7.74%
6,872.56
6,400.54
7.37%
6,607.60
6,229.93
6.06%
EBITDA
1,881.06
1,603.03
17.34%
1,752.78
1,791.92
-2.18%
1,773.34
1,577.98
12.38%
1,678.10
1,566.14
7.15%
EBIDTM
20.56%
20.37%
19.80%
21.38%
20.51%
19.78%
20.25%
20.09%
Other Income
264.23
105.30
150.93%
117.04
134.81
-13.18%
187.64
157.29
19.30%
120.59
136.00
-11.33%
Interest
101.66
97.75
4.00%
98.21
115.02
-14.61%
92.77
118.48
-21.70%
95.24
112.70
-15.49%
Depreciation
486.82
405.70
20.00%
478.57
444.43
7.68%
464.73
418.53
11.04%
429.19
382.28
12.27%
PBT
1,516.63
1,204.88
25.87%
1,293.04
1,367.28
-5.43%
1,338.15
1,198.26
11.67%
1,274.26
1,207.16
5.56%
Tax
483.06
382.60
26.26%
369.77
432.26
-14.46%
428.72
354.28
21.01%
427.79
390.51
9.55%
PAT
1,033.57
822.28
25.70%
923.27
935.02
-1.26%
909.43
843.98
7.75%
846.47
816.65
3.65%
PATM
11.30%
10.45%
10.43%
11.15%
10.52%
10.58%
10.22%
10.48%
EPS
17.95
14.20
26.41%
15.86
15.56
1.93%
15.67
14.56
7.62%
14.61
14.07
3.84%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
34,935.29
33,653.08
31,723.73
29,001.87
24,855.38
23,455.49
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
Net Sales Growth
9.09%
6.08%
9.39%
16.68%
5.97%
-5.32%
7.26%
18.07%
18.83%
10.42%
 
Cost Of Goods Sold
13,876.09
12,014.40
11,671.89
11,348.78
10,190.48
9,238.91
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
Gross Profit
21,059.20
21,638.68
20,051.84
17,653.09
14,664.90
14,216.58
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
GP Margin
60.28%
64.30%
63.21%
60.87%
59.00%
60.61%
64.37%
62.25%
59.69%
63.04%
60.35%
Total Expenditure
27,850.01
26,835.75
25,140.94
23,158.87
21,136.74
19,070.95
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
Power & Fuel Cost
-
1,117.61
1,012.25
826.03
842.63
626.86
589.28
587.68
556.79
470.95
437.14
% Of Sales
-
3.32%
3.19%
2.85%
3.39%
2.67%
2.38%
2.54%
2.85%
2.86%
2.93%
Employee Cost
-
5,190.17
4,475.62
3,922.94
3,522.25
3,450.92
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
% Of Sales
-
15.42%
14.11%
13.53%
14.17%
14.71%
14.27%
13.94%
13.21%
12.94%
11.86%
Manufacturing Exp.
-
3,760.09
3,556.25
3,191.71
2,810.03
2,502.98
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
% Of Sales
-
11.17%
11.21%
11.01%
11.31%
10.67%
11.61%
10.09%
10.42%
9.79%
8.78%
General & Admin Exp.
-
1,763.42
1,551.60
1,483.77
1,386.66
1,335.03
1,473.59
1,320.69
1,006.68
1,068.22
997.32
% Of Sales
-
5.24%
4.89%
5.12%
5.58%
5.69%
5.95%
5.72%
5.15%
6.49%
6.69%
Selling & Distn. Exp.
-
2,254.93
2,185.06
1,684.72
1,685.76
1,496.67
1,564.17
1,524.75
1,125.76
1,025.85
848.43
% Of Sales
-
6.70%
6.89%
5.81%
6.78%
6.38%
6.31%
6.60%
5.75%
6.23%
5.69%
Miscellaneous Exp.
-
735.13
688.27
700.92
698.93
419.58
576.06
529.75
413.24
298.75
848.43
% Of Sales
-
2.18%
2.17%
2.42%
2.81%
1.79%
2.33%
2.29%
2.11%
1.81%
1.37%
EBITDA
7,085.28
6,817.33
6,582.79
5,843.00
3,718.64
4,384.54
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
EBITDA Margin
20.28%
20.26%
20.75%
20.15%
14.96%
18.69%
21.53%
21.06%
20.20%
22.91%
23.03%
Other Income
689.50
520.49
621.85
557.38
290.59
322.58
380.85
191.87
155.32
101.98
115.89
Interest
387.88
383.97
457.24
289.71
140.48
48.64
74.49
305.13
262.60
77.72
66.72
Depreciation
1,859.31
1,778.19
1,649.42
1,521.66
1,244.58
1,126.52
1,055.39
966.71
667.95
557.97
427.63
PBT
5,422.08
5,175.66
5,097.98
4,589.01
2,624.17
3,531.96
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
Tax
1,709.34
1,608.88
1,582.72
1,211.02
684.85
725.63
2,009.77
899.35
726.85
818.27
759.65
Tax Rate
31.53%
31.48%
31.05%
27.54%
26.10%
21.32%
27.16%
23.93%
23.53%
25.27%
24.86%
PAT
3,712.74
3,504.75
3,485.88
3,172.97
1,927.50
2,648.15
5,334.84
2,845.14
2,364.73
2,423.17
2,301.66
PAT before Minority Interest
3,714.50
3,502.97
3,483.57
3,168.97
1,927.65
2,647.11
5,333.82
2,843.69
2,364.50
2,422.91
2,301.19
Minority Interest
1.76
1.78
2.31
4.00
-0.15
1.04
1.02
1.45
0.23
0.26
0.47
PAT Margin
10.63%
10.41%
10.99%
10.94%
7.75%
11.29%
21.53%
12.32%
12.09%
14.72%
15.44%
PAT Growth
8.63%
0.54%
9.86%
64.62%
-27.21%
-50.36%
87.51%
20.32%
-2.41%
5.28%
 
EPS
64.52
60.91
60.58
55.14
33.50
46.02
92.72
49.45
41.10
42.11
40.00

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
37,890.97
32,653.32
29,842.80
26,839.85
24,575.98
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
Share Capital
58.08
58.08
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.59
Total Reserves
37,832.89
32,595.24
29,784.21
26,781.26
24,517.39
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
Non-Current Liabilities
1,096.74
1,162.74
1,808.94
866.87
903.10
807.27
555.09
358.13
594.11
102.07
Secured Loans
798.20
1,159.38
2,134.90
618.96
249.21
168.49
0.00
48.88
26.96
177.59
Unsecured Loans
4.55
402.27
0.00
0.00
0.00
0.00
0.00
131.07
424.24
3.81
Long Term Provisions
400.41
282.93
225.70
172.72
171.79
157.11
74.71
46.54
55.86
39.13
Current Liabilities
18,039.01
14,682.34
12,199.13
11,493.78
8,155.98
10,665.05
11,384.64
12,020.57
8,665.89
6,605.60
Trade Payables
5,567.27
4,188.85
4,454.16
3,871.31
2,703.05
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
Other Current Liabilities
5,828.46
4,462.78
3,161.05
2,979.91
3,106.51
2,684.31
2,874.56
2,510.51
1,967.42
1,286.82
Short Term Borrowings
6,079.64
5,470.22
4,078.12
4,230.43
2,117.83
4,803.78
5,422.30
6,573.21
4,031.34
2,902.72
Short Term Provisions
563.64
560.49
505.80
412.13
228.59
382.28
511.72
384.67
294.23
261.36
Total Liabilities
57,018.56
48,492.01
43,858.87
39,212.50
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
Net Block
17,406.58
14,794.19
14,492.79
11,023.69
10,532.09
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
Gross Block
29,251.05
24,462.96
23,447.77
18,593.32
15,943.09
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
Accumulated Depreciation
11,844.47
9,668.77
8,952.24
7,569.63
5,411.00
4,239.75
3,044.79
2,022.77
1,374.10
801.71
Non Current Assets
24,309.81
21,329.55
19,653.24
17,666.83
15,510.44
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
Capital Work in Progress
5,213.56
4,899.96
3,868.72
5,390.01
3,747.20
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
Non Current Investment
303.88
251.70
321.65
391.74
618.30
431.22
554.69
360.20
311.52
245.85
Long Term Loans & Adv.
971.58
973.42
714.55
794.00
575.33
658.44
378.34
396.64
261.91
256.48
Other Non Current Assets
414.21
410.28
255.53
67.39
37.52
53.03
36.61
38.62
86.93
81.29
Current Assets
32,708.75
27,162.46
23,771.92
21,459.91
18,043.59
19,739.90
16,412.51
15,332.30
12,178.16
9,206.18
Current Investments
747.24
0.01
50.58
151.00
378.85
159.79
0.02
0.02
0.02
0.02
Inventories
12,052.94
10,543.72
9,808.23
8,511.23
7,553.85
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
Sundry Debtors
7,094.37
5,745.93
4,816.74
4,466.38
4,012.26
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
Cash & Bank
9,870.29
8,235.49
6,278.30
6,084.20
4,190.01
5,474.28
2,842.15
1,957.18
1,262.25
513.48
Other Current Assets
2,943.91
654.00
519.45
554.71
1,908.62
1,575.98
1,555.31
2,715.72
1,977.28
1,596.81
Short Term Loans & Adv.
2,545.16
1,983.31
2,298.62
1,692.39
1,514.67
1,058.30
1,065.96
795.90
753.96
512.09
Net Current Assets
14,669.74
12,480.12
11,572.79
9,966.13
9,887.61
9,074.85
5,027.87
3,311.73
3,512.27
2,600.58
Total Assets
57,018.56
48,492.01
43,425.16
39,126.74
33,554.03
33,317.70
28,764.54
26,271.07
20,942.24
16,081.66

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
5,526.37
3,924.62
2,434.52
2,386.75
5,016.48
3,329.05
4,381.28
1,650.97
1,954.52
3,278.58
PBT
5,111.85
5,066.29
4,379.99
2,612.50
3,372.74
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
Adjustment
2,082.62
1,834.16
1,496.24
1,586.47
1,344.13
-1,662.64
1,091.17
813.95
535.02
408.92
Changes in Working Capital
163.93
-1,244.48
-1,675.07
-1,094.98
1,557.80
-1,066.65
307.91
-1,484.50
-1,123.12
582.52
Cash after chg. in Working capital
7,358.40
5,655.97
4,201.16
3,103.99
6,274.67
4,614.30
5,142.12
2,420.80
2,653.08
4,052.28
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,832.03
-1,731.35
-1,766.64
-717.24
-1,258.19
-1,285.25
-760.84
-769.83
-698.56
-773.70
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,458.61
-1,875.80
-4,255.95
-3,977.75
-3,211.56
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
Net Fixed Assets
-543.55
-141.97
2,277.63
-503.75
1,473.74
-428.03
-760.60
-799.00
-771.00
-1,092.24
Net Investments
-2,352.78
-1,816.13
-5,288.07
-1,521.01
-1,574.43
-2,482.52
-188.35
-371.56
-285.55
-498.60
Others
-562.28
82.30
-1,245.51
-1,952.99
-3,110.87
3,509.24
-618.69
-1,732.03
-870.04
-196.20
Cash from Financing Activity
-1,269.15
119.78
800.42
1,814.41
-2,969.27
-1,364.94
-1,947.18
1,919.06
864.15
-1,915.26
Net Cash Inflow / Outflow
798.61
2,168.60
-1,021.01
223.41
-1,164.35
2,562.80
866.46
667.44
892.08
-423.72
Opening Cash & Equivalents
5,563.79
3,385.43
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
318.03
743.49
Closing Cash & Equivalent
7,191.40
5,563.79
3,385.43
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
319.63

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
652.39
562.21
509.35
458.10
419.46
374.29
287.16
237.08
199.36
159.96
ROA
6.64%
7.54%
7.63%
5.29%
7.90%
17.34%
10.39%
10.00%
13.07%
14.44%
ROE
9.93%
11.15%
11.18%
7.50%
11.38%
27.81%
18.62%
18.47%
22.99%
27.57%
ROCE
12.76%
14.39%
13.76%
9.39%
12.71%
30.33%
18.79%
17.97%
22.72%
24.92%
Fixed Asset Turnover
2.59
2.65
2.84
2.95
3.24
3.73
4.12
4.36
2.44
2.96
Receivable days
33.71
30.33
28.34
30.42
28.69
29.37
29.85
29.56
64.66
89.16
Inventory Days
59.32
58.44
55.92
57.65
63.29
62.82
57.72
59.64
112.70
101.43
Payable days
148.20
135.14
133.88
117.74
108.60
111.03
53.30
58.56
67.77
75.73
Cash Conversion Cycle
-55.17
-46.37
-49.62
-29.67
-16.62
-18.84
34.27
30.63
109.58
114.86
Total Debt/Equity
0.20
0.24
0.21
0.18
0.10
0.23
0.33
0.50
0.41
0.36
Interest Cover
14.31
12.08
16.12
19.60
70.34
100.33
13.32
12.76
42.66
46.80

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • USFDA completes inspection at Aurobindo Pharma’s arm’s Andhra Pradesh facility
    11th Sep 2026, 17:51 PM

    The inspection was conducted from September 7 to September 11, 2026 and concluded with zero observations

    Read More
  • Aurobindo Pharma’s arm incorporates wholly owned subsidiary
    1st Sep 2026, 13:05 PM

    The object of incorporation of this wholly owned subsidiary is to undertake manufacturing and marketing operations in India and foreign countries

    Read More
  • Aurobindo Pharma’s arm launches generic equivalent of Advair Diskus in US market
    31st Aug 2026, 10:58 AM

    Advair Diskus in combination therapy is indicated for the treatment of asthma and chronic obstructive pulmonary disease

    Read More
  • USFDA completes inspection at Aurobindo Pharma’s arm’s Andhra Pradesh facility
    28th Aug 2026, 17:27 PM

    The inspection concluded with three observations, which are procedural in nature

    Read More
  • Aurobindo Pharma’s arm receives four observations from USFDA
    24th Aug 2026, 15:41 PM

    The USFDA conducted a routine inspection at Lannett Company LLC from August 17 to August 21, 2026

    Read More
  • USFDA concludes inspection at Aurobindo Pharma’s AuroPeptides with one observation
    24th Aug 2026, 09:28 AM

    The USFDA conducted inspection at AuroPeptides from August 17 to 21, 2026

    Read More
  • Aurobindo Pharma incorporates wholly owned subsidiary
    14th Aug 2026, 09:06 AM

    The object of incorporation of this wholly owned subsidiary is to undertake manufacturing and marketing operations in India and foreign countries

    Read More
  • Aurobindo Pharma enters into non-exclusive voluntary licensing agreement with MSD
    25th Jul 2026, 10:28 AM

    Aurobindo Pharma is among a select group of global generic manufacturers to have signed this agreement

    Read More
  • Aurobindo Pharma’s arm gets ANVISA’s nod for biosimilars manufacturing facility in Hyderabad
    21st Jul 2026, 18:05 PM

    The approval strengthens the company's capability to supply biosimilar products to the Brazilian and broader Latin American markets

    Read More
  • Aurobindo Pharma’s arm incorporates subsidiary in Indonesia
    10th Jul 2026, 16:59 PM

    The object of incorporation of this wholly owned stepdown subsidiary is to undertake manufacturing operations in Indonesia

    Read More
  • Aurobindo Pharma’s arm completes acquisition of Lannett Company
    30th Jun 2026, 11:18 AM

    Lannett has become a wholly owned subsidiary of Aurobindo Pharma USA Inc

    Read More
  • USFDA completes inspection at Aurobindo Pharma’s arm’s Andhra Pradesh facility
    29th Jun 2026, 10:30 AM

    The inspection concluded with 2 observations and will be responded to within the stipulated time

    Read More
  • Aurobindo Pharma’s arm gets US FTC’s approval to acquire Lannett
    22nd Jun 2026, 09:08 AM

    The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to close before the end of June 2026

    Read More
  • USFDA completes PAI at Aurobindo Pharma’s arm’s Andhra Pradesh facility
    20th Jun 2026, 15:20 PM

    The inspection concluded with 5 observations

    Read More
  • Aurobindo Pharma’s arm gets US FTC’s nod for acquiring 100% of membership interest in Lannett
    19th Jun 2026, 12:59 PM

    This acquisition strengthens its ability to serve the U.S. generics space and provides strategic diversification into a specialized, high-value therapeutic category

    Read More
  • USFDA inspects Aurobindo Pharma’s arm’s Eugia Unit-III in Telangana
    13th Jun 2026, 14:41 PM

    The inspection had concluded with 11 observations

    Read More
  • Aurobindo Pharma gets USFDA’s final nod for Tofacitinib Tablets
    5th Jun 2026, 09:50 AM

    The product will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company and will be launched immediately

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.